Skip to main navigation

Overview
News & Events
- News Releases
- Events & Presentations
Governance
Financials
- SEC Filings
- IRS Form 8937
Stock
Resources

News Releases

Year

08 Aug '24

Carisma Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

06 Aug '24

Carisma Therapeutics Announces Expansion of Its Scientific Advisory Board

06 Aug '24

Carisma Therapeutics Announces Upcoming Presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024

01 Jul '24

Carisma Therapeutics Announces Changes to its Board of Directors

27 Jun '24

Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna

25 Jun '24

Carisma Therapeutics Granted FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid Tumors

25 Jun '24

Carisma Therapeutics to Participate in the Stifel 2024 Cell Therapy Forum

13 Jun '24

Carisma Therapeutics Announces Adjournment of Annual Meeting of Stockholders

30 May '24

Carisma Therapeutics to Participate in the Jefferies Global Healthcare Conference

16 May '24

Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
Next page
Last page

Displaying 11 - 20 of 31

Site - Investor Tools

Print Page
Email Alerts
RSS Feeds
IR Contact

Request Email Alerts

© 2024 Carisma Therapeutics Inc. All rights reserved.